August 2, 2025DiagnosticsOpen Access

Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication

View Full Paper

Ask AI

Bookmark

Authors

BRBlerina ResuliLMU Klinikum DKDiego Kauffmann‐GuerreroGerman Center for Lung Research MLM. LassoLMU Klinikum

Discussion

Member takes

Implication

Systematic review compares outcomes of various immunotherapy regimens in patients with advanced NSCLC, indicating PD-1 blockade may offer better results.

Key Points

PD-1-targeted therapies showed improved overall survival compared to PD-L1 regimens, especially cemiplimab monotherapy.
Atezolizumab plus chemotherapy demonstrated the best progression-free survival outcomes among evaluated regimens.
Combination therapies achieved higher overall response rates but were linked to increased adverse events.
Balancing efficacy and safety is vital in the treatment of advanced NSCLC, necessitating personalized therapy approaches.

Cite This Study

Resuli et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d00b6 https://doi.org/10.3390/diagnostics15151937

View Full Paper

Ask AI

Bookmark

Implication

Systematic review compares outcomes of various immunotherapy regimens in patients with advanced NSCLC, indicating PD-1 blockade may offer better results.

Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication

Discussion

Member takes

Implication

Key Points

Cite This Study

Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider